Analystreport

Horizon Therapeutics PLC (NASDAQ: HZNP) had its price target raised by analysts at BMO Capital Markets to $40.00. They now have an "outperform" rating on the stock.

Horizon Therapeutics Public Limited Company - Ordinary Shares  (HZNP) 
Last horizon therapeutics public limited company - ordinary shares earnings: 2/26 07:00 am Check Earnings Report